Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Corvus Pharmaceuticals

Corvus Pharmaceuticals?uq=8lCq2teR
2014 FOUNDED
PUBLIC STATUS
51-60 EMPLOYEES
CRVS STOCK SYMBOL
$8.86 SHARE PRICE (As of Friday Closing)
Description

Operator of a biopharmaceutical company designed to provide treatment of cancer. The company offers new drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 863 Mitten Road
  • Suite 102
  • Burlingame, CA 94010
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Corvus Pharmaceuticals’s full profile, request a free trial.

Corvus Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$7.48 - $16.93 $275M $9.42 -$2.21 80.9K 29.2M

Corvus Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Jun-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 176,613 83,091 204,655
EBITDA (51,166) (55,682) (36,382) (31,222)
Net Income (50,578) (55,663) (36,375) (31,335)
Total Assets 137,919 94,775 140,150 98,459
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Corvus Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Corvus Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Corvus Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Corvus Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Corvus Pharmaceuticals Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Corvus Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Corvus Pharmaceuticals Executive Team (10)

Name Title Board
Seat
Contact
Info
Richard Miller MD Co-Founder, Chief Executive Officer, President & Board Member
Leiv Lea Chief Financial Officer
Joseph Buggy Ph.D Co-Founder & Advisor, Strategy
Erik Verner Ph.D Vice President, Chemistry Research
William Jones Ph.D Vice President of Pharmaceutical Development

2 Former Executives

You’re viewing 5 of 10 executives. Get the full list »

Corvus Pharmaceuticals Board Members (6)

Name Representing Role Since Contact
Info
Elisha Gould Self President & Chairman 000 0000
Peter Thompson MD Self Co-Founder & Board Member 000 0000
Richard Miller MD Corvus Pharmaceuticals Co-Founder, Chief Executive Officer, President & Board Member 000 0000
Scott Morrison Corvus Pharmaceuticals Board Member 000 0000

2 Former Board Members

You’re viewing 4 of 6 board members. Get the full list »